Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating

MT NewswiresDec 17 02:34 · Ratings

Leerink Partners Maintains PepGen(PEPG.US) With Buy Rating

Futu NewsDec 17 02:32 · Ratings

BofA Securities Downgrades PepGen(PEPG.US) to Sell Rating, Cuts Target Price to $3

Futu NewsDec 17 01:32 · Ratings

PepGen Shares Tumble Premarket as FDA Puts Study on Clinical Hold

WSJDec 16 21:29

PepGen Announces Clinical Hold In The U.S. On IND Application To Initiate CONNECT2-EDO51 Phase 2 Study Of PGN-EDO51 For Duchenne Muscular Dystrophy; Continues To Advance PGN-EDO51 In CONNECT1-EDO51, With The 10 Mg/kg Cohort Now Fully Enrolled

BenzingaDec 16 21:12

Express News | PepGen Announces Clinical Hold in the U.S. on Ind Application to Initiate Connect2-Edo51 Phase 2 Study of Pgn-Edo51 for Duchenne Muscular Dystrophy

BreakingsDec 16 21:00